References (Services)

ReachBio Services
Reference
Cell Banking (Antigen Presenting Cells) Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” D’Alessandro J.S.,1 Duffner J.,1 Pradines J.,1 Capila I.,1 Garofalo K.,1 Kaundinya G.,1 Greenberg B.M.,2 Kantor D.,3 Ganguly T.C.,1. PLoS One: 1-19, 2015 Oct 16;10(10), doi: 10.1371/journal.pone.0140299. 1Momenta Pharmaceuticals, Inc., Cambridge, MA, USA; 2The University of Texas Southwestern Medical Center, Dallas, TX, USA; 3 Kantor Neurology, Coconut Creek, FL, USA.
Human and mouse bone marrow toxicity studies (Chemotherapeutic Agents) 14-Aminocamptothecin: Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment,” Duan J.X.,1 Cai X.,1 Sun J.,1 Meng F.,1 Liu Q.,1 Bhupathi D.,1 Ahluwalia D.,1 Huang H.,1 Jung D.,1 Hart C.,1 Matteucci M.,1 American Association for Cancer Research 101st Annual Meeting 2010, Poster Abstract No. 762 . 1Threshold Pharmaceuticals, Redwood City, CA, USA.
Human bone marrow toxicity studies (Tyrosine Kinase Inhibitors) “MP-470, a Novel Multi-Targeted Tyrosine Kinae Inhibitor Targeting Rad 51 is Not Toxic to Human Primary Marrow Stem Cells at Clinically Relevant Concentrations,” Joshi R.,1 Kanekal S.,1 Redkar S.,1 Berk G.,1 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2008, Poster Abstract No. 480 . 1Supergen Inc., Dublin, CA, USA.
Human and mouse bone marrow toxicity studies (Microtubule Inhibitor targeting Tumors) A Novel Microtubule Inhibitor 4SC-207 with Anti-Proliferative Activity in Taxane-Resistant Cells,” Bausch E.,1 Kohlhof H.,2 Hamm S.,3 Krauss R.,2 Baumgartner R.,2 Sironi L.,1 PLOS one, 8(11): 1-14, November 2013. 1 Department of Biology and Konstanz Research School Chemical Biology, University of Konstanz, Konstanz, Germany, 2 4SC AG, Planegg – Martinsried, Germany, 3 4SC Discovery GmbH, Planegg, Martinsried, Germany.
Human bone marrow toxicity studies (Myelosuppressive Oncology Drugs) Setting occupational exposure limits for unstudied pharmaceutical intermediates using an in vitro parallelogram approach,” Maier M.,1 Toxicology Mechanisms and Methods, 21(2): 76–85, 2011. 1Cambrex Corporation, Charles City, IA, USA.
Human bone marrow toxicity studies (Anti-Viral Combination drug studies) Inhibition of Hepatitis C Virus Replicon RNA Synthesis by PSI-352938, a Cyclic Phosphate Prodrug of β-D-2’-Deoxy-2’-α-Fluoro-2’-β-C-Methylguanosine,” Lam A.,1 Espiritu C.,1 Murakami E.,1 Zennou V.,1 Bansal S.,1 Micolochick Steuer H.M.,1 Niu, C.,1 Keilman M.,1 Bao H.,1 Bourne N.,2 Veselenak R.L.,2 Reddy P.G.,1 Chang W.,1 Du J.,1 Nagarathnam D.,1 Sofia M.J.,1 Otto M.J.,1 Furman P.A.,1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(6): 2566–2575, June 2011. 1Pharmasset, Inc., Princeton, NJ, 2University of Texas Medical Branch, Galveston, TX.
Human and mouse bone marrow toxicity studies (Chemotherapeutic Agents) 14-Aminocamptothecins: Their Synthesis, Preclinical Activity, and Potential Use for Cancer Treatment,” Duan J.X.,1 Cai X.,1 Meng F.,1 Sun J.,1 Liu Q.,1 Jung D.,1 Jiao H.,1 Matteucci J.,1 Jung B.,1 Bhupathi D.,1 Ahluwalia D.,1 Huang H.,1 Hart C.,1 Matteucci M.,1 J. Med. Chem, 54: 1715-1723, 2011. 1Threshold Pharmaceuticals, Redwood City, CA, USA.
Human bone marrow toxicity studies (Anti-Viral Combination drug studies) Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661,” Furman P.A.,1 Murakami E.,1 Niu C.,1 Lam A.M.,1 Espiritu C.,1 Bansal S.,1 Bao H.,1 Tolstykh T.,1 Micolochick Steuer H.,1 Keilman M.,1 Zennou V.,1 Bourne N., 2 Veselenak R.L.,2 Chang W.,1 Ross B.S.,1 Du J.,1 Otto M.J.,1 Sofia M.J.,1 Antiviral Research, 91: 120–132, 2011. 1Pharmasset, Inc., East Princeton, NJ, USA, 2University of Texas Medical Branch, Galveston, TX, USA.
Human bone marrow toxicity studies (Anti-Viral drug study) PSI-7851, a Pronucleotide of β-ᴅ-2’-Deoxy-2’-Fluoro-2’-C-Methyluridine Monophosphate, Is a Potent and Pan Genotype Inhibitor of Hepatitis C Virus Replication,” Lam A.M.,1 Murakami E.,1 Espiritu C.,1 Micolochick Steuer H.M,1 Niu C.,1 Keilman M.,1 Bao H.,1 Zennou V.,1 Bourne N.,2 Julander J.G.,3 Morrey J.D.,3 Smee D.F.,3 Frick D.N.,4 Heck J.A.,4 Wang P.,1 Nagarathnam D.,1 Ross B.S.,1 Sofia M.J.,1 Otto M.J.,?1 Furman P.A.,1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54(8): 3187–3196, Aug 2010. 1Pharmasset, Inc., Princeton, NJ; 2University of Texas Medical Branch, Galveston,TX; 3Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT; 4Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY.
Human bone marrow toxicity studies (Anti-Viral drug study) Discovery of a β-ᴅ-2’-Deoxy-2’-α-fluoro-2’-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus,” Sofia M.J.,1 Bao D.,1 Chang W.,1 Du J.,1 Nagarathnam D.,1 Rachakonda S.,1 Reddy P.G.,1 Ross B.S.,1 Wang P.,1 Zhang H.,1 Bansal S.,1 Espiritu C.,1 Keilman M.,1 Lam A.M.,1 Micolochick-Steuer H.M.,1 Niu C.,1 Otto M.J.,1 Furman P.A.,1 J. Med. Chem., 53: 7202–721, 2010.  1Pharmasset, Inc., Princeton, NJ.